• Chief Clinical Officer, Dana-Farber Cancer Institute
  • Professor of Medicine, Harvard Medical School

Dr. Bruce Johnson is the Chief Clinical Research Officer at the Dana-Farber Cancer Institute (DFCI), a Professor of Medicine at Harvard Medical School, and an Institute Physician at DFCI and Brigham and Women’s Hospital.  He served as President of the American Society of Clinical Oncology (ASCO) for the 2017-2018 term.

He is one of the investigators who discovered the association between epidermal growth factor receptor mutations and EGFR-tyrosine kinase inhibitors, and is devoted to investigating novel therapeutic agents for their efficacy against lung cancer. 

Dr. Johnson received his undergraduate degree from Harvard University, his medical degree from the University of Minnesota, trained in Internal Medicine at the University of Chicago, and completed his training at the National Cancer Institute where he headed their Lung Cancer Biology section for six years.

Presentation at BIOHK2021

Topic: Application of Precision Medicine for Patients with Lung Cancer, Predictive Biomarkers for both Targeted Therapies and Checkpoint Inhibitors.

Don’t miss out on this opportunity to learn about novel and most innovative advances in cancer diagnostics and therapy at BIOHK2020